The European Medicines Agency just announced yet another extension for the testing of Nitrosamines contamination.

‍

‍

The Step 1 risk evaluation for products containing chemically synthesised APIs should now be concluded and reported by 31st March 2021, and for those containing biological APIs, by 1st July 2021.

As per the previous guidance, all MAHs should inform the concerned Competent Authorities within their own country of the outcome of their risk evaluation using the dedicated portal where it exists, or via the dedicated templates available on the EMA website.

Furthermore, the Step 2 confirmatory testing for products containing chemically synthesised APIs are expected to be finalized at the latest by 26th September 2022 and for products containing biological APIs, by 1st July 2023.

The extension certainly relieves a little pressure on the pharma industry, but there is no guarantee of further extensions, so it’s advisable to act now.

Visit our Nitrosamines overview page to find out more, and discover why QUINTA-ANALYTICA have become european leaders in the field of nitros detection.

Additional News

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

ALL POSTS